BR112012013496A2 - "composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral". - Google Patents

"composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral".

Info

Publication number
BR112012013496A2
BR112012013496A2 BR112012013496A BR112012013496A BR112012013496A2 BR 112012013496 A2 BR112012013496 A2 BR 112012013496A2 BR 112012013496 A BR112012013496 A BR 112012013496A BR 112012013496 A BR112012013496 A BR 112012013496A BR 112012013496 A2 BR112012013496 A2 BR 112012013496A2
Authority
BR
Brazil
Prior art keywords
prevention
antibody composition
suppression
oral application
composition
Prior art date
Application number
BR112012013496A
Other languages
English (en)
Portuguese (pt)
Inventor
April Roberts
Clifford Shone
John Landon
Original Assignee
Health Prot Agency
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2010/050288 external-priority patent/WO2010094970A1/en
Application filed by Health Prot Agency, Micropharm Ltd filed Critical Health Prot Agency
Publication of BR112012013496A2 publication Critical patent/BR112012013496A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012013496A 2009-12-04 2010-12-06 "composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral". BR112012013496A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection
PCT/GB2010/050288 WO2010094970A1 (en) 2009-02-20 2010-02-19 Antibodies to clostridium difficile toxins
PCT/GB2010/052035 WO2011067616A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection

Publications (1)

Publication Number Publication Date
BR112012013496A2 true BR112012013496A2 (pt) 2016-08-16

Family

ID=41641956

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013496A BR112012013496A2 (pt) 2009-12-04 2010-12-06 "composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral".

Country Status (10)

Country Link
US (1) US8921529B2 (https=)
EP (1) EP2506877B1 (https=)
JP (1) JP5877161B2 (https=)
CN (1) CN102740889A (https=)
BR (1) BR112012013496A2 (https=)
CA (1) CA2782639C (https=)
GB (1) GB0921288D0 (https=)
MY (1) MY158712A (https=)
SG (1) SG181127A1 (https=)
WO (1) WO2011067616A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010215275B2 (en) 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
SG11201400916XA (en) * 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN105142612A (zh) 2013-03-08 2015-12-09 奇普拉股份有限公司 用于直肠给药的药物组合物
KR20150133771A (ko) * 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
SG11201700089QA (en) * 2014-07-25 2017-02-27 Biosynth Srl Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
EP0779819A1 (en) 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
NZ295998A (en) * 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
US20070265187A1 (en) * 2004-04-29 2007-11-15 Slobodan Vukicevic Oral Formulations Comprising Bone Morphogenetic Proteins For Treating Metabolic Bone Diseases
WO2006071877A2 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
AU2010215275B2 (en) 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
WO2011067616A1 (en) 2011-06-09
CA2782639C (en) 2019-02-26
GB0921288D0 (en) 2010-01-20
CA2782639A1 (en) 2011-06-09
EP2506877A1 (en) 2012-10-10
EP2506877B1 (en) 2021-08-04
JP2013512889A (ja) 2013-04-18
US8921529B2 (en) 2014-12-30
US20130004561A1 (en) 2013-01-03
JP5877161B2 (ja) 2016-03-02
CN102740889A (zh) 2012-10-17
SG181127A1 (en) 2012-07-30
MY158712A (en) 2016-11-15
AU2010325764A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
BR112012013496A2 (pt) "composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral".
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112012001297A2 (pt) conector.
BR112012010705A2 (pt) composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112012006010A2 (pt) composto de glicina
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
MX2013005727A (es) Composicion para ser usada en la prevencion de infecciones agudas del tracto respiratorio y/o para aliviar los sintomas de dichas infecciones.
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112015022092A8 (pt) derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo
BR112013007380A2 (pt) regime de administração para nitrocatecóis
WO2007128086A3 (en) Novel viral replication inhibitor
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112013025630A2 (pt) derivados de piridopirazina e seu uso
CL2010001174A1 (es) Uso de espironolactona, sus polimorfos, hidratos o solvatos para preparar un medicamento util para prevenir y/o tratar la esclerosis muiltiple.
BR112018010107A8 (pt) Composição farmacêutica para o tratamento ou prevenção de nash
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MICROPHARM LIMITED (GB) , THE SECRETARY OF STATE F

B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]